Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Expired

Improving the Care Process for Patients with Advanced Prostate Cancer

Pfizer

The American Urological Association Education and Research, Inc. (AUAER) and Pfizer Medical Grants & Partnerships (GMGP) are collaborating to offer grant support to urology health institutions and organizations to identify gaps in patient care for individuals with advanced prostate cancer (APC) and develop solutions-based projects to address these gaps. APC is a diverse and clinically heterogeneous disease state encompassing biochemical recurrence, metastatic hormone-sensitive prostate cancer (mHSPC), nonmetastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant prostate cancer (mCRPC), requiring treatments tailored to the individual patient. Patient identification is paramount for evaluating appropriate treatment options. Furthermore, analysis of a patient’s germline and somatic tumor genomic alterations can help inform prognosis and predict treatment effectiveness. Over the past several decades treatment advances have yielded improvements in patient quality of life and survival, however, prostate cancer still accounts for 11% of all cancer-related deaths in men in the United States.1 As the landscape for men with APC continues to evolve, therapy sequencing, treatment intensification and combinations, and the expansion of precision medicine are increasingly important factors to ensure successful outcomes. AUAER is committed to being forward-thinking and innovative to align stakeholders of the urologic community to achieve better urologic health and urologic healthcare for all patients. Pfizer’s GMGP supports the global healthcare community’s independent initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer and Astellas via the “Pfizer-Astellas Alliance” are collaborating to provide independent grant support in the area of prostate cancer. For all independent grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. The companies must not be involved in any aspect of project development, nor the conduct, of the independent education program.

This RFP is being issued by all three organizations. AUAER is the lead organization for review and evaluation of proposals. A review committee, led by AUAER, will make decisions on which proposals will receive funding. Grant funding and general oversight of the funded projects will be provided directly from Pfizer on behalf of the Pfizer-Astellas Alliance. Collectively, $1.5 Million USD is available for award.

RFP Intent

This RFP intends to encourage proposals to fund novel quality improvement projects that address barriers to optimal care for patients with APC, which include those with biochemical recurrence at high-risk for metastasis, nonmetastatic castration-resistant prostate cancer (nmCRPC), low- or high-volume metastatic hormonesensitive prostate cancer (mHSPC), and metastatic castration-resistant prostate cancer (mCRPC), including those with germline and somatic genomic alterations. Many factors contribute to the complexity of treating APC, including:

• Identifying patients who may be appropriate candidates for intensified or combination therapy.

• Coordinating care across multidisciplinary team members and locations of care.

• Integrating rapidly advancing treatment options, including access to biomarker and genetic testing, and next generation imaging.

• Effectively sequencing therapies to treat APC.

• Introducing appropriate treatment intensification for patients with APC.

• Appropriately managing toxicities of approved therapies.

• Navigating the discrepancies between national treatment guidelines.

• The complexity of ensuring an adequate health care workforce, which often results in patient access issues. Proposed projects should measurably improve patient care by closing the gap between how patients with APC are currently being managed and how patients should be optimally treated and cared for.

RFP Scope

AUAER and Pfizer are interested in funding projects that meet one or more of the following:

• Foster multidisciplinary team involvement, including advanced practice providers (APPs) and genetic counselors, to enhance shared decision-making with patients.

• Optimize referral processes from urology to medical oncology.

• Improve therapy management.

• Sequencing strategies in urology/oncology practices, including combination approaches and integration of new treatments (e.g., PARPi).

• Develop systematic approaches to conducting biomarker and genetic testing for patients.

• Improve access to treatment and diagnostics through improving adherence to AUA and NCCN Guidelines.

• Patient follow-up and close collaboration with Primary Care Physicians, who often monitor patients for PSA post- and during treatment.

If an education intervention is proposed as part of a quality improvement project, please consider the existing guidelines, resources, and education provided by the AUA. Education can be found on AUAUniversity, the AUAUniversity YouTube Channel and the AUAUniversity podcast. If patient education materials are proposed, please consider using materials from the Urology Care Foundation which are free to all providers and patients. Special consideration will be given to proposals that:

• Address disparities in APC care for those marginalized due to age, race, income, accessibility, or other factors.

• Propose a project team that is comprised of diverse perspectives and experiences.

• Provide sustainable and potentially transferable solutions that improve the quality of care. This RFP will NOT support clinical research projects evaluating the efficacy of therapeutic or diagnostic agents.

Specialties

Cancer

Oncology

Urology

Healthcare Delivery

Public Health

Eligibility Requirements

• Only organizations are eligible to receive grants, not individuals.

• Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions, organizations, and associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.

• The applicant must be the Project Lead or an authorized designee of such an individual (e.g., the Project Lead’s grant/research coordinator).

• The Project Lead must be an employee or contractor of the requesting organization.

• The requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution before applying. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

• For projects offering continuing education credit, the requesting organization must be accredited

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: Pfizer

Sponsor Type:

Address: 66 Hudson Boulevard East New York, NY 10001-2192 USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity